Committee for Advanced Therapies (CAT): 11-12 September 2024, European Medicines Agency, Amsterdam, the Netherlands, from 11 September 2024 to 12 September 2024
Clinical development of medicinal products for the treatment and prevention of bipolar disorder
Draft guideline on clinical development of medicinal products for the treatment and prevention of bipolar disorder - Revision 1
Applications for new human medicines under evaluation: September 2024
Human medicines European public assessment report (EPAR): Repatha, evolocumab, Date of authorisation: 17/07/2015, Revision: 26, Status: Authorised
Herbal medicinal product: Soiae oleum raffinatumArray, D: Draft under discussion
Herbal medicinal product: MasticArray, F: Assessment finalised
Human medicines European public assessment report (EPAR): Savene, dexrazoxane, Date of authorisation: 27/07/2006, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Ivabradine Accord, ivabradine, Date of authorisation: 22/05/2017, Revision: 7, Status: Authorised
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024